Please click here to log in with you RCPsych web account details; you will be redirected back to CPD Online.If you have forgotten your College web account details, you will be able to reset them here.
Please click here to log in if your institution has a subscription to CPD Online with Athens access.
Please click here to log in if you are subscribed through Medicom Netherlands.
If you having troubles signing in with the options above, please try this alternative login route.
Module home Module introduction Module information About the author
Learning notes
Pre-module test
Section 1: Treatment of antidepressant-induced sexual dysfunction
(1.1) Section 1: Treatment of antidepressant-induced sexual dysfunction
(1.2) Before you begin
(1.3) Clinical vignette: a woman who thought she was 'frigid'
(1.4) Comment: a woman who thought she was 'frigid'
(1.5) Reflection
(1.6) Suggested answers
(1.7) Reflection
(1.8) Suggested answers
(1.9) Overview of treatment strategies
(1.10) Modification of the current antidepressive treatment
(1.11) Treatment of sexual dysfunction targeting specific receptors
(1.12) Other treatments
(1.13) Reflection
(1.14) Pharmacological reversal: target noradrenaline
(1.15) Interactive exercise: outlook: autoreceptors
(1.16) Reflection
(1.17) Pharmacological reversal: target serotonin
(1.18) Reflection
(1.19) Pharmacological reversal: target dopamine
(1.20) Reflection
(1.21) Pharmacological reversal: other targets
(1.22) Pharmacological reversal: target nitric oxide (NO)
(1.23) Phosphodiesterase5 (PD5)-inhibitors head to head
(1.24) Phosphodiesterase5 (PD5)-inhibitors
(1.25) It all starts with nitric oxide…
(1.26) PD5-inhibitors: contraindications and warnings - what your patient should know
(1.27) Yet another story...
(1.28) Alprostadil
(1.29) Female sexual dysfunctions: licensed pharmacological treatments
(1.30) Female sexual dysfuction: drugs that remain controversial
(1.31) Section 1: Recap
(1.32) Section 1: Summary
Section 2: Other treatments for sexual dysfunction
(2.1) Section 2: Other treatments for sexual dysfunction
(2.2) Reflection
(2.3) Suggested answers
(2.4) Hormone treatments for women
(2.5) Why has HRT fallen out of favour with women?
(2.6) HRT: what does it mean for the individual patient?
(2.7) Hormone treatments for women - potential adverse effects
(2.8) Reflection
(2.9) Suggested answers
(2.10) Hormone treatments for men
(2.11) Outlook
(2.12) Reflection
(2.13) Suggested answers
(2.14) Complementary medicines for sexual dysfunction
(2.15) Recommending complementary medicines: issues
(2.16) Hypomanic episodes
(2.17) Outlook
(2.18) Section 2: Recap
(2.19) Section 2: Summary
Section 3: Formal aspects of prescribing for sexual dysfunction
(3.1) Section 3: Formal aspects of prescribing for sexual dysfunction
(3.2) Prescribing unlicensed medications: recommendations
(3.3) The GMC requirements for prescribing unlicensed medications
(3.4) Informed consent
(3.5) The criteria for informed consent: quick recap
(3.6) Reimbursement for treatments
(3.7) The BNF requirements for prescribing for erectile dysfunction
(3.8) The severe distress clause
(3.9) Section 3: Recap
(3.10) Section 3: Summary
Module summary
Module test
Acknowledgements
Send feedback
Useful resources
Take-home notes
References
Further reading